皮肤性病诊疗学杂志2026，Vol.33Issue(8)：580-585,6.DOI:10.3969/j.issn.1674-8468.2026.08.003
赛立奇单抗治疗重度斑块状银屑病的短期疗效与安全性:一项基于真实世界数据的回顾性分析
Short-term efficacy and safety of xeligekimab in severe plaque psoriasis:A retrospective re-al-world study
摘要
Abstract
Objective To evaluate the short-term efficacy and safety of xeligekimab in patients with severe plaque psoriasis based on real-world data,and to perform an exploratory comparison with patients treated with secukinumab during the same period.Methods The clinical data of eli-gible patients with severe plaque psoriasis treated at the Department of Dermatology,Kaifeng Peo-ple's Hospital,between September 2024 and December 2025 were retrospectively analyzed.The xeligekimab group included 23 patients,while the control group comprised 23 patients selected from 52 patients who received secukinumab during the same period using propensity score matc-hing with a caliper value of 0.02.A total of 46 patients were included in the final analysis.The psoriasis area and severity index(PASI)scores and PASI 75/90/100 response rates were com-pared between the groups at baseline and at weeks 4 and 12.Investigator global assessment(IGA)scores and adverse reactions were also recorded.Results After matching,baseline char-acteristics showed no statistically significant differences between the two groups(all P values＞0.05).At weeks 4 and 12,PASI scores decreased significantly compared with baseline in both groups(xeligekimab group:t=20.75 and 24.23,respectively;secukinumab:t=20.85 and 23.01,respectively;all P＜0.001).IGA scores also decreased significantly at week 12 in both groups(xeligekimab:Z=-4.28;secukinumab:Z=-4.26;both P＜0.001).No significant between-group differences were observed in PASI 75/90/100 response rates at weeks 4 and 12(all P values＞0.05).The overall incidence of adverse events was 8.70%(2/23)in the xe-ligekimab group and 13.04%(3/23)in the secukinumab group,with no statistically significant difference(P=1.000).Conclusions Xeligekimab showed favorable short-term efficacy and ac-ceptable safety in the treatment of severe plaque psoriasis.The secukinumab reference group showed a similar pattern of clinical improvement.However,given the non-randomized,exploratory nature of this study,these findings warrant further validation in prospective studies.关键词
银屑病/赛立奇单抗/司库奇尤单抗/临床疗效/安全性Key words
psoriasis/xeligekimab/secukinumab/clinical efficacy/safety引用本文复制引用
张文文,靳旺洋,蔡璐璐,顿耿..赛立奇单抗治疗重度斑块状银屑病的短期疗效与安全性:一项基于真实世界数据的回顾性分析[J].皮肤性病诊疗学杂志,2026,33(8):580-585,6.基金项目
开封市科技发展计划项目(2307009) （2307009）
